# Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis

> **NCT02224456** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 197 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT02224456
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-25
- **Primary completion:** 2020-12-04
- **Final completion:** 2020-12-04
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224456, "Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02224456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*